BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World J Gastroenterol 2017; 23(14): 2545-2555 [PMID: 28465639 DOI: 10.3748/wjg.v23.i14.2545] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
2 Chen X, Fu C, Wang Y, Wu Q, Meng X, Xu K. Mitochondria-targeting nanoparticles for enhanced microwave ablation of cancer. Nanoscale 2018;10:15677-85. [PMID: 30091769 DOI: 10.1039/c8nr03927e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 5.3] [Reference Citation Analysis]
3 Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc 2021;84:606-13. [PMID: 33871391 DOI: 10.1097/JCMA.0000000000000530] [Reference Citation Analysis]
4 Rehman O, Jaferi U, Padda I, Khehra N, Atwal H, Mossabeh D, Bhangu R. Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma. Clin Exp Hepatol 2021;7:249-57. [PMID: 34712825 DOI: 10.5114/ceh.2021.109312] [Reference Citation Analysis]
5 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Heinrich S, Sprinzl M, Schmidtmann I, Heil E, Koch S, Czauderna C, Heinrich B, Philippe P Diggs L, Wörns MA, Kloeckner R, Galle PR, Marquardt JU, Weinmann A. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterol J 2020;8:444-52. [PMID: 32213028 DOI: 10.1177/2050640620904524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Vishnevsky VA, Ayvazyan KA, Ikramov RZ, Ionkin DA, Zhavoronkova OI, Stepanova YA, Varava AB, Kovalenko YA, Zharikov YO, Goncharov AB, Olifir AA, Pakhomova AY, Bugaev SA, Zhao AV. Modern principles of hepatocellular carcinoma treatment. Ann hir gepatol 2020;25:15-26. [DOI: 10.16931/1995-5464.2020215-26] [Reference Citation Analysis]
8 Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Müller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M. Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. Liver Cancer 2019;8:203-17. [PMID: 31192156 DOI: 10.1159/000489833] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
9 Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515. [PMID: 33425223 DOI: 10.4081/oncol.2020.515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Yang J, Zhu S, Yong J, Xia L, Qian X, Yang J, Hu X, Li Y, Wang C, Peng W, Zhang L, Deng M, Pan W. A Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatocellular Carcinoma: Single-Center Analyses With Internal Validation. Front Oncol 2021;11:616976. [PMID: 33747929 DOI: 10.3389/fonc.2021.616976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Xiao Z, Yan Y, Zhou Q, Liu H, Huang P, Zhou Q, Lai C, Zhang J, Wang J, Mao K. Development and external validation of prognostic nomograms in hepatocellular carcinoma patients: a population based study. Cancer Manag Res 2019;11:2691-708. [PMID: 31118768 DOI: 10.2147/CMAR.S191287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
12 Hsu CY, Liu PH, Ho SY, Hsia CY, Kudaravalli P, Lee YH, Chiou YY, Tsai YJ, Huang YH, Huo TI. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer 2018;18:289. [PMID: 29540157 DOI: 10.1186/s12885-018-4202-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ridder DA, Schindeldecker M, Weinmann A, Berndt K, Urbansky L, Witzel HR, Heinrich S, Roth W, Straub BK. Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:744. [PMID: 33670206 DOI: 10.3390/cancers13040744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterol J 2019;7:850-8. [PMID: 31316789 DOI: 10.1177/2050640619840199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
15 Tanaka K, Tsuji K, Matsui T, Kang JH, Sakurai Y, Kodama Y, Minami R, Watanabe K, Katanuma A. Potential of PALBI-T score as a prognostic model for hepatocellular carcinoma in alcoholic liver disease. JGH Open 2022;6:36-43. [PMID: 35071786 DOI: 10.1002/jgh3.12705] [Reference Citation Analysis]